# Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

> **NCT04681820** · — · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 200 (estimated)

## Conditions studied

- CML-CP; Mutation;Suboptimal Response or Failure in TKI

## Interventions

- **DRUG:** Flumatinib
- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT04681820
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2023-12
- **Final completion:** 2024-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04681820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04681820, "Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04681820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*